CyBio and Aventis expand their cooperation

New active substance project with a screening system from Jena

19-Dec-2001 - Germany
CyBio AG in Jena and Aventis Pharma are working together on the development of a screening platform for secondary testing and hit profiling of medical active substances. A suitable cooperation agreement has now been reached, for which Aventis is purchasing another complete screening system from Jena. The installation of the system is to be done in three stages of development, the second of which will be completed by March 2002. The parties have agreed to keep the size of the order confidential. The new cooperation agreement marks another milestone in the long-standing cooperation between the two parties. With its newly acquired screening system, Aventis Pharma in Germany will now have a total of four fully-automatic testing platforms by CyBio. The initial test results of the joint development project are expected as early as the coming year. By supplying Aventis with the Cybi?-Screen-machine, CyBio AG has also reached its yearly goal of selling five complete systems. The Jena biotechnology firm is expecting a continued increase in demand during the coming fiscal year, not least thanks to newly developed system components that will complement the screening systems and further increase the number of applications for them.

Other news from the department science

Most read news

More news from our other portals

Discover the latest developments in battery technology!